Related references
Note: Only part of the references are listed.Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy
Farzana Alam et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile
Bianka Sobolewska et al.
OPHTHALMOLOGICA (2015)
Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor
Farzana Alam et al.
JOURNAL OF APPLIED TOXICOLOGY (2015)
Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid
Farzana Alam et al.
BIOMATERIALS (2014)
Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge
Seung Woo Chung et al.
BIOMATERIALS (2012)
Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor
Asarasin Adulnirath et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Heparin Mimetic Peptide Nanofibers Promote Angiogenesis
Rashad Mammadov et al.
BIOMACROMOLECULES (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
I. Debergh et al.
BRITISH JOURNAL OF CANCER (2010)
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Kristina M. Cook et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor
Esak Lee et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Discovery of heparin chemosensors through diversity oriented fluorescence library approach
Shenliang Wang et al.
CHEMICAL COMMUNICATIONS (2008)
PI-88: a novel inhibitor of angiogenesis
Ragini Kudchadkar et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: Emerging links
Shaker A. Mousa
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2007)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
Henk. M. W. Verheul et al.
NATURE REVIEWS CANCER (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165
JH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist
C Pisano et al.
GLYCOBIOLOGY (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors
A Abramsson et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
RH Cao et al.
NATURE MEDICINE (2003)
Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat
J Liu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Roles of heparan-sulphate glycosaminoglycans in cancer
R Sasisekharan et al.
NATURE REVIEWS CANCER (2002)
Novel drug development opportunities for heparin
R Lever et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Mechanisms of angiogenesis and arteriogenesis
P Carmeliet
NATURE MEDICINE (2000)
Share Paper
